this piece corresponds to the legacy myPDB login in the form of a bootstrap modal, will likely retire-->

DA2

NG,NG-DIMETHYL-L-ARGININE

DA2 is found in 12 entries

DA2 in polymers: 8 entries. Examples include: 2V86 4MZF 2B2U

DA2 as free ligands, exist in 4 entries. Example includes: 4M5A 4A4H 4A4G

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo



Chemical Component Summary

NameNG,NG-DIMETHYL-L-ARGININE
Identifiers(2S)-2-amino-5-[(N,N-dimethylcarbamimidoyl)amino]pentanoic acid
FormulaC8 H18 N4 O2
Molecular Weight202.25 g/mol
TypeL-PEPTIDE LINKING
Isomeric SMILESCN(C)C(=N)NCCC[C@H](N)C(O)=O
InChIInChI=1S/C8H18N4O2/c1-12(2)8(10)11-5-3-4-6(9)7(13)14/h6H,3-5,9H2,1-2H3,(H2,10,11)(H,13,14)/t6-/m0/s1
InChIKeyYDGMGEXADBMOMJ-LURJTMIESA-N

Chemical Details

Formal Charge0
Atom Count32
Chiral Atom Count1
Chiral AtomsCA
Bond Count31
Aromatic Bond Count0
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB01686 Stereoisomeric match
NameN,N-dimethylarginine
Groupsexperimental
DescriptionAsymmetric dimethylarginine (ADMA) is a naturally occurring chemical found in blood plasma. It is a metabolic by-product of continual protein modification processes in the cytoplasm of all human cells. It is closely related to L-arginine, a conditionally-essential amino acid. ADMA interferes with L-arginine in the production of nitric oxide, a key chemical to endothelial and hence cardiovascular health. [Wikipedia]
Synonyms
  • ADMA
  • Asymmetric dimethylarginine
  • dimethyl-L-arginine
  • Guanidino-n,n-dimethylarginine
  • L-NG,NG-dimethylarginine
Affected OrganismHumans and other mammals
PharmacologyAsymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is formed by methylation of arginine residues in proteins and released after proteolysis. In this reaction, S-adenosylmethionine is methyldonor and S-adenosylhomocysteine the demethylated product. ADMA and homocysteine are thus biochemically linked. Both plasma homocysteine and ADMA concentrations are increased in patients with renal dysfunction, probably as a result of an impairment in their metabolic, but not urinary, clearance. Hyperhomocysteinemia has been associated with an increased risk of cardiovascular disease in end-stage renal disease, especially in patients without malnutrition and inflammation. Also, plasma ADMA levels have been associated with cardiovascular disease in renal failure patients. Both homocysteine and ADMA are thought to mediate their adverse vascular effects by impairing endothelial, nitric oxide-dependent function resulting in decreased vasodilatation, increased smooth muscle cell proliferation, platelet dysfunction and increased monocyte adhesion.
Categories
  • Amino Acids
  • Amino Acids, Basic
  • Amino Acids, Diamino
  • Amino Acids, Essential
  • Amino Acids, Peptides, and Proteins
CAS number30315-93-6
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682